Navigation Links
Catabasis Pharmaceuticals Announces Issuance of Patents for CAT-1000 and CAT-2000 Series
Date:4/30/2013

treat complex human diseases such as inflammatory and metabolic diseases."

About CAT-1004CAT-1004 is a new chemical entity that is a conjugate of the omega-3 fatty acid docosahexaenoic acid (DHA) and salicylate. Catabasis' lead program amplifies the beneficial effects of omega-3 fatty acids and salicylate to target inflammation, an underlying cause of many chronic diseases. A growing body of peer-reviewed research, along with clinical experience, has demonstrated important therapeutic benefits of DHA and eicosapentaenoic acid (EPA). Salicylates are anti-inflammatories with proven clinical efficacy and safety, and have been used safely for years to treat inflammatory bowel disease and other diseases of inflammation. Inhibition of NF-kB in muscle satellite cells has been hypothesized to have a beneficial effect in Duchenne muscular dystrophy. Catabasis recently announced positive Phase 1 data for CAT-1004 showing it was safe and well tolerated and that the technology allowed the active components to synergistically inhibit the NF-kB pathway. Phase 2 studies are being planned to evaluate the safety and efficacy of CAT-1004 in patients with inflammatory bowel disease and as a replacement for corticosteroids in patients with Duchenne muscular dystrophy.

About CAT-2003CAT-2003 is a new chemical entity that is a conjugate of the B vitamin niacin and eicosapentaenoic acid (EPA), an omega-3 fatty acid, linked using the company's proprietary SMART Linker technology. It is being investigated for the treatment of severe hypertriglyceridemia. In preclinical models of severe hypertriglyceridemia, a significant and dose-dependent reduction in plasma triglycerides was observed with CAT-2003, while a simple combination of niacin and omega-3 had only a marginal effect. In preclinical models of dyslipidemia, CAT-2003 dramatically reduced LDL cholesterol. In combination with a statin, CAT-2003 synergistically lowered LDL cholesterol. Because CAT-2003 is not activated unti
'/>"/>

SOURCE Catabasis Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Catabasis Initiates Phase 1 Trial of CAT-2003 for Treatment of Severe Hypertriglyceridemia
2. Selexis SA Sells Rights to Royalty Payments for More Than 15 Biologic Development Programs to Ligand Pharmaceuticals
3. Oramed Pharmaceuticals to Present Results of its Key Clinical Studies of Oral Insulin in Type 1 Diabetes Patients at the GTC Diabetes Summit, Boston, MA; April 29-30, 2013
4. Auxilium Pharmaceuticals Completes Acquisition Of Actient Holdings LLC To Create A Leading Urology Franchise With A Diversified Product Portfolio And Strong Growth Profile
5. Absorption Pharmaceuticals to Receive Patent for Premature Ejaculation Topical Medication
6. Novartis Pharmaceuticals Corporation disputes allegations in two US Government lawsuits and looks forward to a fair discussion of the facts
7. Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Thursday, May 2
8. Avanir Pharmaceuticals Receives Positive CHMP Opinion for Approval of NUEDEXTA in Europe
9. Cumberland Pharmaceuticals To Announce First Quarter 2013 Financial Results On May 2, 2013
10. Horizon Technology Finance Closes $2 Million Venture Loan Facility with New Haven Pharmaceuticals
11. Auxilium Pharmaceuticals to Announce First Quarter 2013 Results and Conduct Conference Call on Monday, April 29, 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... Colo. , Aug. 22, 2014  Cannabis ... in cannabis formulation-based drug development and related consulting, ... iCare,s third international medical cannabis conference taking place ... Strasbourg, France , on October 22, 2014.  ... other stakeholders, such as researchers, health professionals, and ...
(Date:8/22/2014)... - SQI Diagnostics Inc. (TSX-V: SQD), a life ... and products for advanced microarray diagnostics, today announced ... Agreement to contract with a UK-based company to ... initial phase of this agreement, SQI will be ... one of the customer,s assays, operational on SQI,s ...
(Date:8/21/2014)... , Aug. 21, 2014  Aptuit LLC ... West Lafayette, Indiana , has enhanced its ... characterization of small and large molecules, including biologic ... the Bruker maXisPlus Q-TOF mass spectrometer. ... , CEO, Aptuit, said, "The expanded large molecule ...
Breaking Medicine Technology:Cannabis Science, Inc. (CBIS) to Sponsor 3rd International Conference on Cannabinoids in Medicine in October 2014 in Strasbourg, France 2Cannabis Science, Inc. (CBIS) to Sponsor 3rd International Conference on Cannabinoids in Medicine in October 2014 in Strasbourg, France 3SQI Diagnostics Contracted to Automate Pathogen Detection Assays 2SQI Diagnostics Contracted to Automate Pathogen Detection Assays 3Aptuit SSCI Adds Ultra High Resolution Q-TOF Mass Spectrometer for Large & Small Molecule Analyses 2
... SYDNEY, May 23, 2011 Starpharma Holdings Limited (ASX: ... major phase 2 clinical study that demonstrated efficacy of ... Key Points: VivaGel(R) ... BV VivaGel(R) expected to avoid many shortcomings of ...
... Mass., May 20, 2011 Philips ... Philips FilterLine H Set and VitaLine H Set ... November 2010 through March 2011.ProductProduct DescriptionProduct Lot CodesM1923A ... M8330M10M8386N10M8411P10M8451P10M8477A11M8514A11M8572B11989803159581 , Philips Vitaline H Set Infant/Neo ...
Cached Medicine Technology:VivaGel(R) Demonstrates Efficacy in Bacterial Vaginosis 2VivaGel(R) Demonstrates Efficacy in Bacterial Vaginosis 3VivaGel(R) Demonstrates Efficacy in Bacterial Vaginosis 4VivaGel(R) Demonstrates Efficacy in Bacterial Vaginosis 5Recall of Infant and Neonatal-Sized FilterLine H Set and VitaLine H Set Sampling Lines 2
(Date:8/22/2014)... FL (PRWEB) August 22, 2014 ... treatment facility in Lantana, FL, recently launched a ... just looking for information can now find Millennium ... new website just went live at the beginning ... about the facility can be found on the ...
(Date:8/22/2014)... Beat Eczema , Susan Clark’s ... natural methods to completely cure the eczema symptoms they ... Shane Michaels, prompting an investigative review. , “Although ... it can still be extremely debilitating and life-altering for ... itching and pain that it causes on the skin ...
(Date:8/22/2014)... in advanced non-small cell lung cancer (NSCLC) is ... epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ... deletion independently predicts overall survival (OS) of advanced ... the programmed cell death also known as the ... detected in 12.8% of the Asian population but ...
(Date:8/22/2014)... receptor (EGFR) mutations found in the circulating free tumor ... lung cancer (NSCLC) patients correlates well with the EGFR ... kinase inhibitor (TKI) therapy is approved for EGFR activating ... for determining mutation status is with DNA derived directly ... available. A more abundant and less invasive source of ...
(Date:8/22/2014)... August 22, 2014 Paying tuition and ... in the coming year for four nurse educators pursuing ... National League for Nursing Foundation for Nursing Education . ... share $28,000, $10,000 more than in 2013, thanks to ... Endowment and Elizabeth Isaac Marcil Endowment Funds, both donated ...
Breaking Medicine News(10 mins):Health News:Millennium Treatment Group Has a New Website 2Health News:Beat Eczema: Review Exposes Susan Clark’s Guide to Curing Eczema Naturally 2Health News:Deletion predicts survival in advanced non-small cell lung cancer 2Health News:High concordance between EGFR mutations from circulating-free tumor DNA and tumor tissue in non-small cell lung cancer 2Health News:NLN Foundation for Nursing Education Announces 2014 Faculty Scholarship Awards 2Health News:NLN Foundation for Nursing Education Announces 2014 Faculty Scholarship Awards 3
... has been aroused in the identification and isolation of ... of bone marrow cells have been found to have ... on immunological methods is difficult because of the complicated ... of successful passage has been published., A research article ...
... , , WEDNESDAY, April 15 (HealthDay News) -- If you have ... or pop in a CD of mellow songs. , Hospital ... rate and blood pressure just by listening to music, a ... report, published in the latest issue of The Cochrane ...
... Delcath Systems, Inc. (Nasdaq: DCTH ) ... PM Eastern Time on Wednesday, April 22, 2009. Richard ... will host the call.(Logo: http://www.newscom.com/cgi-bin/prnh/20081118/NY46990LOGO ... parties may dial (888) 790-3326 (U.S./Canada) and use Conference ...
... MOUNTAIN VIEW, Calif., April 15 Based on ... tomography (PET) and PET/computed tomography (CT) markets market, ... the 2009 North American Frost & Sullivan Award ... forth innovative scintillation crystal and solid-state photo detector ...
... CITRUS HEIGHTS, Calif., April 15 In response ... (EHR) for all patients, SMART Association, Inc. and ... their LifeMed(TM) Smart Card Platform software for EHRs. ... ("HIEs"), hospital legacy systems, or physicians, record management ...
... need to evaluate options for continuing healthcare coverage , ... ... the 2009 American Recovery and Reinvestment Act (ARRA) may be crucial ... people with disabilities no longer able to work, according to ...
Cached Medicine News:Health News:Soothing Songs Please the Heart 2Health News:Delcath Systems to Host Quarterly Update Conference Call 2Health News:Frost & Sullivan Recognizes Zecotek Photonic's Medical Imaging Achievement, Development of Next-Generation Scintillation Crystals and Photo Detector Technology 2Health News:Frost & Sullivan Recognizes Zecotek Photonic's Medical Imaging Achievement, Development of Next-Generation Scintillation Crystals and Photo Detector Technology 3Health News:Frost & Sullivan Recognizes Zecotek Photonic's Medical Imaging Achievement, Development of Next-Generation Scintillation Crystals and Photo Detector Technology 4Health News:SMART Association, Inc. Launches Its Health Information Exchange Software 2Health News:SMART Association, Inc. Launches Its Health Information Exchange Software 3Health News:Jobless Should Evaluate COBRA, Medicare in Light of 2009 Recovery Act 2Health News:Jobless Should Evaluate COBRA, Medicare in Light of 2009 Recovery Act 3Health News:Jobless Should Evaluate COBRA, Medicare in Light of 2009 Recovery Act 4
Utrata-like fine angled tips with gently curved shaft for performing capsulorhexis through tunnel incisions. Dull finish. Round handle manufactured in titanium....
Utrata-like fine angled tips with gently curved shaft for performing capsulorhexis through tunnel incisions. Dull finish. Flat handle....
McPherson handle. 45 degree angled shafts. Manufactured in titanium....
This cross action forcep has delicate tips for grasping the capsule. The forcep has an iris stop to prevent inadvertent grasping of the iris....
Medicine Products: